Orforglipron and Cardiovascular Risk Biomarkers in Type 2 Diabetes and Obesity: An Exploratory Phase 2 Analysis
An exploratory secondary analysis of two Phase 2 trials reports that oral orforglipron lowered blood pressure, LDL cholesterol, triglycerides, ApoB, ApoC3, and hsCRP versus placebo, though no cardiovascular events were measured. PICO summary and expert commentary.
